NEW YORK,
June 7,
2023 /PRNewswire/ -- The Gross Law Firm issues the
following notice to shareholders of Fulcrum Therapeutics,
Inc..
Shareholders who purchased shares of FULC during
the class period listed are encouraged to contact the firm
regarding possible lead plaintiff appointment. Appointment as lead
plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/fulcrum-loss-submission-form/?id=40402&from=4
CLASS PERIOD: March
3, 2022 to March 8, 2023
ALLEGATIONS: The complaint alleges that
during the class period, Defendants issued materially false and/or
misleading statements and/or failed to disclose that: (i) the
preclinical data submitted in support of FTX-6058 (an
investigational oral fetal hemoglobin inducer for the treatment of
sickle cell disease and other hemoglobinopathies) showed safety
concerns regarding potential hematological malignancies; (ii) the
foregoing safety concerns increased the likelihood that the FDA
would place a clinical hold on preclinical studies of FTX-6058;
(iii) accordingly, the Company had overstated FTX-6058's clinical
and/or commercial prospects; and (iv) as a result, the Company's
public statements were materially false and misleading at all
relevant times.
DEADLINE: June 27,
2023 Shareholders should not delay in registering for
this class action. Register your information here:
https://securitiesclasslaw.com/securities/fulcrum-loss-submission-form/?id=40402&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you
register as a shareholder who purchased shares of FULC during the
timeframe listed above, you will be enrolled in a portfolio
monitoring software to provide you with status updates throughout
the lifecycle of the case. The deadline to seek to be a lead
plaintiff is June 27, 2023. There is
no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is
a nationally recognized class action law firm, and our mission is
to protect the rights of all investors who have suffered as a
result of deceit, fraud, and illegal business practices. The Gross
Law Firm is committed to ensuring that companies adhere to
responsible business practices and engage in good corporate
citizenship. The firm seeks recovery on behalf of investors who
incurred losses when false and/or misleading statements or the
omission of material information by a company lead to artificial
inflation of the company's stock. Attorney advertising. Prior
results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-fulcrum-therapeutics-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-june-27-2023--nasdaq-fulc-301844390.html
SOURCE The Gross Law Firm